Physician profile
Atam Singh
NPI 1548271166
$9,088.79
in general payments reported to CMS, 2019-2025
44 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $1,774 · 2021: $921 · 2022: $1,033 · 2023: $1,314 · 2024: $1,107 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,828.47 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,200.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $948.43 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $896.77 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $542.11 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $513.14 | 2019-2025 | Synthroid, Ubrelvy |
| Dexcom, INC. | $473.60 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $461.16 | 2019-2023 | |
| Abbott Laboratories | $398.11 | 2019-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $363.22 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 770g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.83 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $323.25 | 2019-2022 | |
| Corcept Therapeutics | $262.61 | 2022-2025 | Korlym |
| Mannkind Corporation | $253.26 | 2020-2025 | Afrezza |
| Ascensia Diabetes Care US INC. | $239.02 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $148.61 | 2022-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $135.40 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $132.90 | 2020-2025 | Crysvita |
| Medtronic Minimed, INC. | $124.25 | 2019-2020 | |
| Horizon Therapeutics Plc | $106.53 | 2020-2023 | Tepezza |
| Antares Pharma, INC. | $89.91 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Cequr Corporation | $85.24 | 2023-2024 | Cequr Simplicity |
| Amryt Pharma Holdings LTD | $77.54 | 2022-2023 | Mycapssa |
| Radius Health, INC. | $77.03 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $75.55 | 2021-2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $74.94 | 2022-2025 | Gvoke Hypopen |
| Shire North American Group INC | $73.19 | 2019 | |
| Ibsa Pharma INC. | $69.50 | 2020-2024 | Tirosint, Licart |
| Kyowa Kirin, INC. | $66.43 | 2023-2025 | Crysvita |
| Insulet Corporation | $63.63 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $55.40 | 2023-2024 | |
| Senseonics, Incorporated | $55.00 | 2019-2020 | |
| Halozyme INC | $45.09 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.75 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $32.84 | 2023-2024 | Contrave |
| Chiesi USA, INC. | $27.58 | 2025 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $27.39 | 2019 | |
| Sequel Med Tech, LLC | $24.88 | 2025 | Twiist |
| Beta Bionics, INC. | $24.67 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Averitas Pharma INC. | $23.55 | 2024 | Qutenza |
| Madrigal Pharmaceuticals | $23.52 | 2025 | Rezdiffra |
| Pfizer INC. | $22.35 | 2023 | |
| Esperion Therapeutics, INC. | $22.00 | 2020 | |
| Idorsia Pharmaceuticals US INC | $21.24 | 2023 | Quviviq |
| Tolmar, INC. | $16.57 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atam Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.